- Home
- YALA vs NVCR Comparison
YALA vs NVCR Comparison
Compare YALA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | NVCR |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United Arab Emirates | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | YALA | NVCR |
|---|---|---|
| Price | $6.01 | $17.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.08 |
| AVG Volume (30 Days) | 242.1K | ★ 1.7M |
| Earning Date | 05-18-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $16.40 | $7.72 |
| Revenue Next Year | $7.13 | $6.74 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $5.96 | $9.82 |
| 52 Week High | $9.29 | $20.05 |
Technical Indicators
Market Signals| Indicator | YALA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.28 | 65.65 |
| Support Level | $5.96 | $12.66 |
| Resistance Level | $7.27 | $18.92 |
| Average True Range (ATR) | 0.22 | 0.97 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 4.09 | 68.38 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.